ProQR Remains Confident In Pipeline After Sepofarsen Flop, Analysts Not So Much

The company is pinning hopes on its Usher syndrome and retinitis pigmentosa programs, but the disconnect between Phase I/II success and Phase II/III failure dented analysts’ enthusiasm.